

# Joint Models for Personalized Scheduling of Invasive Procedures

Dimitris Rizopoulos

Lifetime Data Science, Pittsburgh, USA

May 30, 2019

# Background & Motivation

# Prostate Cancer (PC)

- PC is the 2nd most frequently diagnosed cancer in males worldwide
  - the most frequent in economically developed countries
- Many countries run population screening programs using PSA blood tests
  - to identify men who have developed the disease
  - or men who have high risk of developing it
- However, these programs have resulted to high rates of over-diagnosis and overtreatment
  - standard treatments have serious side-effects

# Prostate Cancer Active Surveillance

- To avoid over-treatment, men with low grade prostate cancer are advised active surveillance
- Cancer progression is tracked via:
  - Prostate-specific antigen measurements
  - Digital rectal examination
  - Biopsies
- Treatment is advised when cancer progression is observed
  - typically via biopsies


# Biopsies vs. Delay in Cancer Detection

- Biopsies

- are the current gold standard
- but burdensome (pain, complications)


- Cancer Progression

- can only be detected with a certain delay




# Annual Biopsies

- Focus on minimizing delay
  - maximum delay can be 1 year
- Many unnecessary biopsies for patients who progress slow



# Less Frequent Biopsies - 1

- PRIAS
  - every 3 years or
  - annually if PSA doubling time < 10 (try to find faster progressions)



# Less Frequent Biopsies - 2

- Still unnecessary biopsies
  - based on simulations, 4-10 unnecessary biopsies for patients with progression >10 years
- PRIAS reports low compliance (~20%) for annual biopsy due to PSA-DT



## Less Frequent Biopsies - 3

Considerable room to improve biopsy  
scheduling


# A New Approach - 1

- Scheduling based on individualized risk predictions
  - Progression rate is not only different between patients but also dynamically changes over time for the same patient
- Risk predictions based upon
  - All available PSA (ng/mL) measurements
  - All available DRE (T1c / above T1c) measurements
  - Time and results of previous biopsies

# A New Approach - 2

Outcome:

subject PSA



# A New Approach - 3

How to better plan biopsies?

- In steps:
  - *How the longitudinal PSA & DRE are related to Gleason reclassification?*
  - *How to combine previous PSA & DRE measurements and biopsies to predict reclassification?*
  - *When to plan the next biopsy?*

# Modeling Framework

# Time-varying Covariates

- To answer these questions we need to link
  - the time to Gleason reclassification (survival outcome)
  - the PSA measurements (longitudinal continuous outcome)
  - the DRE measurements (longitudinal binary outcome)
- Biomarkers are *endogenous* time-varying covariates
  - their future path depends on previous events
  - standard time-varying Cox model not appropriate



# Time-varying Covariates (cont'd)

To account for endogeneity we use the framework of

**Joint Models for Longitudinal & Survival Data**

# The Basic Joint Model

Measurements:





# The Basic Joint Model (cont'd)

- We need some notation
  - $T_i^*$  the true reclassification time
  - $T_i^L$  last biopsy time point Gleason Score was  $< 7$
  - $T_i^R$  first biopsy time point Gleason Score was  $\geq 7$
  - $T_i^R = \infty$  for patients who haven't been reclassified yet
  - $\mathbf{y}_{i1}$  vector of longitudinal PSA measurements
  - $\mathcal{Y}_{i1}(t) = \{y_{i1}(s), 0 \leq s < t\}$
  - $\mathbf{y}_{i2}$  vector of longitudinal DRE measurements
  - $\mathcal{Y}_{i2}(t) = \{y_{i2}(s), 0 \leq s < t\}$

# The Basic Joint Model (cont'd)

- Formally, we have

$$\left\{ \begin{array}{ll} h_i(t) & = h_0(t) \exp\{\gamma^\top \mathbf{w}_i + \alpha_1 \eta_{i1}(t) + \alpha_2 \eta_{i2}(t)\} \\ y_{i1}(t) & = \eta_{i1}(t) + \varepsilon_i(t) \\ & = \mathbf{x}_{i1}^\top(t) \beta_1 + \mathbf{z}_{i1}^\top(t) \mathbf{b}_{i1} + \varepsilon_i(t) \\ \log \frac{\Pr\{y_{i2}(t)=1\}}{1-\Pr\{y_{i2}(t)=1\}} & = \eta_{i2}(t) \\ & = \mathbf{x}_{i2}^\top(t) \beta_2 + \mathbf{z}_{i2}^\top(t) \mathbf{b}_{i2} \\ & \{b_{i1}, b_{i2}\} \sim \mathcal{N}(\mathbf{0}, \mathbf{D}), \quad \varepsilon_i(t) \sim \mathcal{N}(0, \sigma^2) \end{array} \right.$$

# The Basic Joint Model (cont'd)

- The longitudinal and survival outcomes are jointly modeled

$$p(y_{i1}, y_{i2}, T_i^L, T_i^R) = \int p(y_{i1} \mid b_{i1}) p(y_{i2} \mid b_{i2}) \times \\ \{S(T_i^L \mid b_i) - S(T_i^R \mid b_i)\} p(b_i) db_i$$

- the random effects  $b_i$  explain the interdependencies

# Functional Form



- Biomarker's rate of change
  - fast increasing PSA indicative of progression

$$h_i(t) = h_0(t) \exp\{\gamma^\top \mathbf{w}_i + \alpha_1 \eta_{i1}(t) + \alpha_2 \eta'_{i1}(t)\}$$

where  $\eta'_{i1}(t) = \frac{d}{dt} \eta_{i1}(t)$

# Functional Form (cont'd)

times:




# **A Model for PRIAS**

# Joint Model for PRIAS - 1

- Submodel for biomarkers
  - $\log_2$  PSA trajectories: Age effect + nonlinear evolutions over time
  - DRE > T1c trajectories: Age effect + linear evolutions over time
- Submodel for Risk of Gleason reclassification
  - Age effect
  - log odds of DRE > T1c
  - $\log_2$  PSA level
  - $\log_2$  PSA velocity


# Joint Model for PRIAS - 2






# Joint Model for PRIAS - 3

- Area under the receiver operating characteristic curve (AUC)
- Discrimination ability (progression vs. others) in a 1 year time window



# Joint Model for PRIAS - 4

- Prediction Error for predicting progression vs. others, in a 1 year time window



# Personalizing Biopsy Scheduling

# Personalized Decision Methodology - 1

- A new patient, a new visit
  - At some follow-up time, with a certain history of PSA, DRE and biopsies
  - We combine this information using the joint model, to obtain risk of cancer progression at that visit
- How to select when to perform a biopsy?
  - **Solution 1:** A fixed threshold, 15% within a year
    - however, the same for all time points

# Personalized Decision Methodology - 2

- How to select when to perform a biopsy?
  - **Solution 2:** Dynamic threshold based on PRIAS
    - we want both high sensitivity and high positive predictive value
    - basically we don't want too many FP or FN

$$F1 = 2 \frac{SN \times PPV}{SN + PPV}$$

- we select the threshold that maximizes the F1 score


# Performance via Simulations

# Personalized vs. Fixed Schedules - 1

- Is it better to work with personalized schedules?
- Simulation study:
  - The same characteristics as in PRIAS
  - 500 datasets x (750 training + 250 test) patients

# Personalized vs. Fixed Schedules - 2

- For illustration purposes, we define:
  - Slow progression: patients who never progress (50%)
  - Remaining 50%:
    - Fast progression: 30% progression in 0 to 3.5 years
    - Intermediate progression: 20% progression in 3.5 to 10 years





# Personalized vs. Fixed Schedules - 3

- Fixed:
  - PRIAS (biopsy every 3 years, and if PSA goes up too fast then annual biopsy)
  - Annual (annual biopsies)
- Personalized (risk based):
  - 5% risk threshold
  - 15% risk threshold
  - time dependent threshold based on F1 score

# Personalized vs. Fixed Schedules - 4

- Comparison criteria
  - Number of biopsies until cancer progression
  - Delay in detection of cancer progression

# Simulation Results


Patient Selection:

All patients

Fast (30% patients)

Intermediate (20% patients)

Slow (50% patients)



# Discussion

- Things to improve
  - account for miss-classification
- Biometrics paper available at:  
<https://onlinelibrary.wiley.com/doi/10.1111/biom.12940>  
(<https://onlinelibrary.wiley.com/doi/10.1111/biom.12940>)
- Software: available in **JMbayes** on CRAN & GitHub
  - <https://cran.r-project.org/package=JMbayes> (<https://cran.r-project.org/package=JMbayes>)
  - <https://github.com/drizopoulos/JMbayes>  
(<https://github.com/drizopoulos/JMbayes>)

**Thank you for your attention!**

<http://www.drizopoulos.com/> (http://www.drizopoulos.com/)